4/16
08:11 pm
ostx
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes [Yahoo! Finance]
Low
Report
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes [Yahoo! Finance]
4/14
07:35 am
ostx
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor [Yahoo! Finance]
Neutral
Report
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor [Yahoo! Finance]
4/11
09:35 am
ostx
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
Low
Report
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
4/10
06:14 pm
ostx
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
Low
Report
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
3/27
06:17 am
ostx
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma [Yahoo! Finance]
Low
Report
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma [Yahoo! Finance]
2/2
06:16 am
ostx
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]
Low
Report
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]